These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 9021651

  • 1. Improved orthostatic tolerance in familial amyloidotic polyneuropathy with unnatural noradrenaline precursor L-threo-3,4-dihydroxyphenylserine.
    Carvalho MJ, van den Meiracker AH, Boomsma F, Man in 't Veld AJ, Freitas J, Costa O, de Freitas AF.
    J Auton Nerv Syst; 1997 Jan 12; 62(1-2):63-71. PubMed ID: 9021651
    [Abstract] [Full Text] [Related]

  • 2. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
    Mathias CJ, Senard JM, Braune S, Watson L, Aragishi A, Keeling JE, Taylor MD.
    Clin Auton Res; 2001 Aug 12; 11(4):235-42. PubMed ID: 11710796
    [Abstract] [Full Text] [Related]

  • 3. d,l-threo-3,4-dihydroxyphenylserine restores sympathetic control and cures orthostatic hypotension in dopamine beta-hydroxylase deficiency.
    Man in 't Veld AJ, Boomsma F, van den Meiracker AH, Julien C, Lenders J, Schalekamp MA.
    J Hypertens Suppl; 1988 Dec 12; 6(4):S547-9. PubMed ID: 3149290
    [Abstract] [Full Text] [Related]

  • 4. The effects of the noradrenaline precursor, L-threo-3,4-dihydroxyphenylserine, in children with orthostatic intolerance.
    Tanaka H, Yamaguchi H, Mino M.
    Clin Auton Res; 1996 Aug 12; 6(4):189-93. PubMed ID: 8902314
    [Abstract] [Full Text] [Related]

  • 5. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
    Birkmayer W, Birkmayer G, Lechner H, Riederer P.
    J Neural Transm; 1983 Aug 12; 58(3-4):305-13. PubMed ID: 6420517
    [Abstract] [Full Text] [Related]

  • 6. Treatment of orthostatic hypotension in Shy-Drager syndrome with DL-threo-3,4-dihydroxyphenylserine: a case report.
    Sakoda S, Suzuki T, Higa S, Ueji M, Kishimoto S, Matsumoto M, Yoneda S.
    Eur Neurol; 1985 Aug 12; 24(5):330-4. PubMed ID: 3932074
    [Abstract] [Full Text] [Related]

  • 7. [Development of L-threo-DOPS, a norepinephrine precursor amino acid].
    Katsube J, Narabayashi H, Hayashi A, Tanaka C, Suzuki T.
    Yakugaku Zasshi; 1994 Nov 12; 114(11):823-46. PubMed ID: 7853146
    [Abstract] [Full Text] [Related]

  • 8. Studies of neurocirculatory effects of long-term L-threo-3,4-dihydroxyphenylserine administration in a patient with familial amyloidotic polyneuropathy.
    Azuma T, Suzuki T, Mizuno R, Tsujino S, Kishimoto S, Mizuta E, Ichikawa K.
    Acta Neurol Scand; 1988 May 12; 77(5):409-13. PubMed ID: 3137768
    [Abstract] [Full Text] [Related]

  • 9. Intranasal L-threo-3,4,-dihydroxyphenylserine in treating diarrhea associated with familial amyloidotic polyneuropathy.
    Ando Y, Gotoh T, Kawaguchi Y, Tanaka Y, Sakashita N, Ando M.
    Pharmacotherapy; 1995 May 12; 15(3):345-9. PubMed ID: 7667168
    [Abstract] [Full Text] [Related]

  • 10. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial.
    Freeman R, Landsberg L, Young J.
    Neurology; 1999 Dec 10; 53(9):2151-7. PubMed ID: 10599797
    [Abstract] [Full Text] [Related]

  • 11. Orthostatic hypotension in familial amyloid polyneuropathy: treatment with DL-threo-3,4-dihydroxyphenylserine.
    Suzuki T, Higa S, Sakoda S, Hayashi A, Yamamura Y, Takaba Y, Nakajima A.
    Neurology; 1981 Oct 10; 31(10):1323-6. PubMed ID: 6287350
    [Abstract] [Full Text] [Related]

  • 12. Clinical effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.
    Akizawa T, Koshikawa S, Iida N, Marumo F, Akiba T, Kawaguchi Y, Imada A, Yamazaki C, Suzuki M, Tubakihara Y.
    Nephron; 2002 Apr 10; 90(4):384-90. PubMed ID: 11961396
    [Abstract] [Full Text] [Related]

  • 13. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
    Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R.
    Circulation; 2003 Aug 12; 108(6):724-8. PubMed ID: 12885750
    [Abstract] [Full Text] [Related]

  • 14. Effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.
    Iida N, Koshikawa S, Akizawa T, Tsubakihara Y, Marumo F, Akiba T, Kawaguchi Y, Imada A, Yamazaki C, Suzuki M.
    Am J Nephrol; 2002 Aug 12; 22(4):338-46. PubMed ID: 12169865
    [Abstract] [Full Text] [Related]

  • 15. Mass spectrometric measurements of norepinephrine synthesis in man from infusion of stable isotope-labelled L-threo-3,4-dihydroxyphenylserine.
    Suzuki T, Sakoda S, Ueji M, Kishimoto S.
    Life Sci; 1985 Feb 04; 36(5):435-42. PubMed ID: 3918223
    [Abstract] [Full Text] [Related]

  • 16. Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension.
    Lamotte G, Holmes C, Sullivan P, Goldstein DS.
    Clin Auton Res; 2019 Feb 04; 29(1):113-117. PubMed ID: 30229336
    [Abstract] [Full Text] [Related]

  • 17. Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase deficiency.
    Man in 't Veld AJ, Boomsma F, van den Meiracker AH, Schalekamp MA.
    Lancet; 1987 Nov 21; 2(8569):1172-5. PubMed ID: 2890807
    [Abstract] [Full Text] [Related]

  • 18. Effect of long-term L-threo-3,4-dihydroxyphenylserine administration on alpha 2-adrenergic receptors in platelet membranes in neurologic disorders.
    Azuma T, Suzuki T, Sakoda S, Mizuno R, Tsujino S, Kobayashi T, Kishimoto S, Hiraga T, Matsubara T, Yoshida S.
    Acta Neurol Scand; 1991 Jul 21; 84(1):46-50. PubMed ID: 1656690
    [Abstract] [Full Text] [Related]

  • 19. DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension.
    Hoeldtke RD, Cilmi KM, Mattis-Graves K.
    Clin Pharmacol Ther; 1984 Sep 21; 36(3):302-6. PubMed ID: 6432398
    [Abstract] [Full Text] [Related]

  • 20. Clinical presentation and long-term follow-up of dopamine beta hydroxylase deficiency.
    Wassenberg T, Deinum J, van Ittersum FJ, Kamsteeg EJ, Pennings M, Verbeek MM, Wevers RA, van Albada ME, Kema IP, Versmissen J, van den Meiracker T, Lenders JWM, Monnens L, Willemsen MA.
    J Inherit Metab Dis; 2021 May 21; 44(3):554-565. PubMed ID: 33034372
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.